Allogeneic transplantation in older and infirm AML patients, cilta-cel in progressive multiple myeloma, and anti-CD20 therapy in relapsed TTP
Blood Podcast
00:00
Siltacelle Therapy in Refractory Multiple Myeloma Patients
Twenty patients were treated with siltacelle, 13 of which had been exposed to antibody drug conjugates and seven to bi-specific antibodies. Eighty percent or 16 of twenty patients were refractory to prior anti-BCMA therapy. Hematologic adverse events were most common.
Transcript
Play full episode
